PERSONALIZED MEDICINE

+

WOMEN'S HEALTH

BIG DATA

+

GENOMICS

GROUND BREAKING RESEARCH

+

WORLD CLASS PRODUCTS

celmatix logo

Celmatix is a personalized medicine company focused on women’s health.

We leverage predictive analytics and genomics to create products that bring greater clarity to the treatment of infertility and pave the way for proactive fertility management.

OUR PRODUCTS

Powered by our novel research discoveries, our products help women make informed decisions about their fertility and provide doctors data-driven tools that complement their patient care.

POLARIS™

The world’s first analytics platform for optimizing a woman’s fertility

Polaris uses big data and predictive modeling to provide a more precise look at a woman’s fertility potential. Currently optimized for fertility clinics, Polaris is the only product in the world that can calculate a woman's personal likelihood of success using different fertility treatment options, tailored to a patient’s clinical metrics.

Flexible modeling that can make projections as early as the initial consultation

Side-by-side comparisons of a patient’s specific likelihoods with timed intercourse, non-IVF, and IVF, today and in the future

Communicates complex information visually

Harnesses the power of 100K+ cycles of real patient data

Frames treatment as a journey, giving doctors the information they need to counsel patients past failed cycles

Web-based and fully HIPAA compliant, Polaris helps doctors simplify complex conversations and enable data-driven decision making.


To learn more or to schedule a demo, Contact Us.

By 2016, we will be launching Polaris X, a companion genetic diagnostic for the Polaris platform that reveals subclinical factors impacting fertility outcomes.

NOVA™

A turnkey patient portal that helps clinics maximize the patient experience

Patients today have more choices than ever. Nova is a patient concierge that helps clinics create a unique, high-touch experience by guiding patients step-by-step through the entire treatment journey. By eliminating paper and giving patients on-demand access to clinic-specific resources and materials, Nova helps clinics elevate the patient experience to match the sophistication of the treatment process.

Digital new patient intake forms

Electronic consent collection and tracking

On-demand access to the clinic’s informational resources and educational tools

Digital checkpoints that reinforce legal and billing compliance

Nova features:

Digital new patient intake forms

Electronic consent collection and tracking

On-demand access to the clinic’s informational resources and educational tools

Digital checkpoints that reinforce legal and billing compliance

Nova can help clinics:

Access patient information from different clinic locations

Have more confidence with new patient billing audits

Reduce paperwork or consent mistakes

Reduce time spent scanning or manually entering new patient information


Web-based, flexible, and fully HIPAA compliant, the Nova platform can be integrated with existing EMRs and gives clinics the power to maximize every new patient lead. Nova also fully integrates with Polaris, which gives doctors a seamless way of communicating a patient's specific likelihood of success using different treatment options now and in the future.

To learn more or to schedule a demo, Contact Us.

OUR RESEARCH

Over the past five years, Celmatix has been developing an unprecedented understanding of reproductive function in humans by leveraging data science and genomics. We believe that both major advances in the treatment of infertility and the ability of women to proactively manage their fertility will arise from the intersection of big data and genomics.

  • Identifying the relationships that are currently hidden inside the vast amounts of clinical data recorded by doctors.


  • Identifying the genetic and sub-clinical factors that may encode or influence a woman’s fertility potential.


  • Our scientists are the first in the world to:

    Develop predictive models that dynamically calculate personalized likelihood of success over time, with and without treatment, now and in the future.

    Identify genetic variants underlying previously unexplained cases of infertility, including IVF non-responders.

    Reveal that up to 25% of IVF patients discontinue treatment while they still have a good likelihood of success

    Observe that mutations in pathways related to egg quality appear to predominate in patients failing IVF for unexplained reasons.

    Demonstrate through a cost effectiveness study that most people would benefit from initiating IVF sooner.

    Define Fertilome™ DNA: the regions of the human genome most likely to encode a woman's fertility potential.

    COLLABORATE

    We are building a research consortium of top fertility clinics across the country that share a commitment to patient-centered research and innovation.

    UCONN | Center for Advanced Reproductive Services
    Washington University | Infertility and Reproductive Medicine Center
    RMA of Michigan
    RMA of New York
    RMA of Philadelphia

    CURRENT RESEARCH STUDIES

    • Genetic biomarker discovery and validation study
    • Prospective validation study of our predictive models in a clinical setting

    To learn more about joining our growing consortium or about our research studies, contact us.

    ABOUT US

    Founded in 2009, Celmatix is a New York City-based personalized medicine company that leverages big data and genomics to create products that bring greater clarity to the treatment of infertility and pave the way for proactive fertility management. We are 20+ people strong and call the Meatpacking District home.

    FEATURED IN

    MEET THE TEAM

    Celmatix’s team includes a diverse group of world-class professionals and scientists, including those with backgrounds in bioinformatics, statistics, and data science.

    Filter team by:
    Founders
    Directors
    Leadership
    Product
    Operations
    Research
    Scientific Advisory Board
    Corporate Advisory Board
    Filter team by:

    RECENT PUBLICATIONS & PRESENTATIONS

    October 2014

    An open letter to the primary ovarian insufficiency community

    September 2014

    Female cystic fibrosis mutation carriers and assisted reproductive technology: does carrier status affect reproductive outcomes?

    September 2013

    Personalized reproductive medicine on the brink: progress, opportunities and challenges ahead

    March 2012

    Patients Need not be Concerned When Their IVF Retrievals and Transfers Fall on a Weekend

    Analysis of the Effects of Phasing out IVF Laboratory Scheduled Maintainence Periods

    October 2014

    Most Patients Would Benefit from Moving More Quickly to IVF: Results from a Cost-effectiveness Analysis of a Large Retrospective Cohort

    Meta-analysis Reveals a Novel Role for Mediators of Active Cell Migration and Axon Guidance in Endometriosis

    Obesity Has a Greater Impact on IVF Success Rates in Patients with PCOS

    October 2013

    Accurate prediction of the number of cycles to achieve live birth

    Targeted resequencing sheds light on the etiology of unexplained female infertilty

    A novel role for genomic copy number variants in female infertility

    Improved determination of ectopic pregnancy risk in patients undergoing in vitro fertilization treatment using time-to-event models

    Patients discontinue assisted reproductive technology (ART) too early: the results of a large multiyear cohort study

    Whole genome sequencing for female infertility biomarker discovery

    October 2012

    Understanding the Incidence, Etiology and Effect of Retained Embryos Following Embryo Transfer

    October 2011

    Daily IVF retrieval variation does not affect patient success rates with high quality equipment and appropriate laboratory staffing